News

Collaboration with ErVaccine Technologies

June 20, 2021 | BALTIMORE –  Complete Omics’ announced a collaboration with ErVaccine Technologies, a pharmaceutical company headquartered in Lyon, Rhone-Alpes, Francey, on a neoantigen validation and quantification project.

Ervaccine Technologies a developer of next-generation cancer vaccines that targets endogenous retroviruses. Complete Omics is proud to work with ErVaccine to leverage our Valid-NEO platform for personalized cancer therapeutics.

Follow by Email
Facebook
Twitter
LinkedIn
Facebook
Twitter
LinkedIn